Upregulated serum miR‐128‐3p in progressive and relapse‐free multiple sclerosis patients

• DOI: 10.1111/ane.13288
• Publication Date: 2020-05-20T17:32:15Z
• Authors: Mattia Zanoni; Elisa Orlandi; Giulia Rossetti; Marco Turatti; Massimiliano Cala...; Macarena Gomez Lira; Alberto Gajofatto
• Keywords: Adult; Male; 0301 basic medicine; mir-128-3p; multiple sclerosis; biomarkers; serum; disease activity; disease progression; Multiple Sclerosis; Middle Aged; 3. Good health; MicroRNAs; 03 medical and health sciences; Recurrence; Disease Progression; Humans; Female; Circulating MicroRNA; Biomarkers

Circulating microRNAs have emerged as novel multiple sclerosis (MS) biomarkers.To assess the association between candidate miR expression in serum samples of patients with MS and the disease course.Serum levels of ten microRNAs (ie, miR-199, miR-128-3p, miR-20a-5p, miR-27a-3p, miR-15b-5p, miR-325, miR-92a1-5p, miR-223-5p, miR-22-5p, and miR-23a-5p) were measured in 74 MS cases and 17 non-MS controls consecutively enrolled at Verona University Hospital. The association of microRNA expression with patients' clinical and MRI features was analyzed. Candidate microRNAs were detected by real-time PCR and expressed as ratio of each microRNA level to a normalizer.Serum miR-128-3p levels were higher in progressive than relapsing MS (median ratio 2.86 vs 0.73, P = .036). In addition, miR-128-3p was upregulated in patients without relapses after sample collection compared to cases who relapsed (1.64 vs 0.82; P = .014). miR-128-3p levels and relapse rate were inversely correlated (r = -.44, P = .008).Serum levels of mir-128-3p could be related to biological mechanisms underlying MS activity and progression.